글로벌 분자적 진료 시점 테스트(NAAT 사용) 시장 – 2028년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 무료 샘플 보고서 무료 샘플 보고서 구매하기 전에 문의 구매하기 전에 문의 지금 구매 지금 구매

글로벌 분자적 진료 시점 테스트(NAAT 사용) 시장 – 2028년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Aug 2022
  • Global
  • 350 Pages
  • 테이블 수: 492
  • 그림 수: 76

글로벌 분자적 진료 시점 검사(NAAT 사용) 시장, 제품별(기구 및 소모품 및 시약), 지표(호흡기 감염 검사, 성병(STI) 검사, 위장관 감염 검사 등), 최종 사용자(실험실, 병원, 진료소, 외래 센터, 홈 케어, 보호 시설 등), 검사 방식(처방 기반 검사 및 OTC 검사), 유통 채널(병원 약국, 소매 약국 및 온라인 약국) - 업계 동향 및 2028년까지의 예측.

분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장

분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장 분석 및 통찰력

글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 의료 시설과 인프라 개선과 병원, 실험실, 진료소에서 말기 검사 도입으로 인해 성장할 것으로 예상되며, 이는 시장 성장을 촉진할 수 있습니다. 분자적 진료 시점 검사(NAAT 사용) 시장 개발을 촉진할 것으로 예상되는 다른 요인으로는 감염성 질환의 유병률 증가가 있습니다.

분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장

숙련된 전문가의 부족과 맞춤형 분자적 진료 시점 검사(NAAT 사용)의 높은 비용과 같은 다른 요인은 글로벌 분자적 진료 시점 검사(NAAT 사용) 시장의 성장을 방해합니다. 반면에, 증가한 의료비와 선진 병원이 있는 신흥국은 글로벌 분자적 진료 시점 검사(NAAT 사용) 시장을 성장시킬 수 있는 기회로 작용합니다.

Data Bridge Market Research에 따르면, 글로벌 분자적 진료 시점 테스트(NAAT 사용) 시장이 2021년부터 2028년까지 연평균 성장률 10.8%로 성장할 것으로 분석되었습니다.

보고서 메트릭

세부

예측 기간

2021년부터 2028년까지

기준 연도

2020

역사적 연도

2019

양적 단위

수익은 백만 달러, 가격은 미화로 표시됨

다루는 세그먼트

제품별(기구 및 소모품 및 시약), 적응증(호흡기 감염 검사, 성병(STI) 검사, 위장관 감염 검사 등), 최종 사용자(실험실, 병원, 진료소, 외래 센터, 홈 케어, 보호 시설 등), 검사 모드(처방 기반 검사 및 OTC 검사), 유통 채널(병원 약국, 소매 약국 및 온라인 약국)

적용 국가

북미(미국, 캐나다), 유럽(영국, 독일, 프랑스, ​​스페인, 이탈리아, 유럽의 나머지 지역), 남아시아(파키스탄, 방글라데시, 인도, 남아시아의 나머지 지역), 동남아시아(싱가포르, 말레이시아, 베트남 인도네시아, 태국, 필리핀, 동남아시아의 나머지 지역), 중동(사우디 아라비아, UAE, 이집트, 이스라엘, 중동의 나머지 지역), 아프리카(남아프리카, 케냐, 나이지리아, 아프리카의 나머지 지역)

시장 참여자 포함

SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc., binx Health, Inc., Lucira, Meridian Bioscience, Quantumdx Group Ltd., BD, Biomérieux Sa, Qiagen, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories, Inc., Sekisui Diagnostic, Randox Laboratories Ltd., GenMark Diagnostics, Seegene Inc. Grifols SA, Wondfo, Oxford Nanopore Diagnostic, PerkinElmer Inc., 및 Co-Diagnostic,

글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장의 시장 정의

POCT는 환자와 가까운 곳에서 수행하여 결과와 모니터링을 포함하여 의학적 결정을 즉시 내릴 수 있는 검사로 특징지어집니다. 현재 임상적으로 사용되는 POCT 장치는 여기에서 2세대 장치로 정의되는 핵산 증폭 기술(NAAT)을 기반으로 합니다. 이러한 플랫폼은 일반적으로 1세대 POCT에 비해 감도가 일반적으로 60~90% 향상되었으며 약 30cm x 30cm 크기의 휴대용 계측기가 필요합니다. 이러한 계측기는 본질적으로 NAAT 기술을 통해 HIV , HPV 및 호흡기 질환과 같은 다양한 질환을 분자적으로 감지하는 데 사용됩니다. NAAT는 DNA 또는 RNA를 감지하여 병원체를 식별할 수 있는 핵산 증폭 기술입니다.

전 세계적 팬데믹 상황에서 NAAT의 민감성과 POCT 검사의 사용 용이성을 결합하려는 시도로, COVID-19의 보다 빠른 스크리닝 및 진단을 위해 소형화된 NAAT 기반 POCT 장치와 검사가 고안되었고, 이로 인해 시장 성장도 촉진되었습니다.

글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장 역학

이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.

운전자

  • 만성 질환 유병률 증가

건강 악화는 연령 증가와 함께 시작된다는 것은 일반적인 사실입니다. 만성 질환의 비율이 시간이 지남에 따라 증가함에 따라 질병 비율과 관련된 요인도 증가합니다. 비만/과체중 인구의 수가 많기 때문에 전 세계 여러 지역에서 만성 질환의 유병률도 증가했습니다. HPV, STI, TB 등과 유사한 만성 질환의 수가 증가함에 따라 사람들은 NAAT 기반 진료소 및 검사 제품을 선택하게 되었습니다. 따라서 이는 향후 몇 년 동안 글로벌 분자 진료소 검사(NAAT 사용) 시장의 성장을 촉진할 것입니다.

  • 진단 요청율 개선

암, 빈혈, 2형 당뇨병 등 만성 질환의 성공적인 진단이 증가함에 따라, 개선된 의료 전문가들은 지역의 진단율 개선을 위해 검사를 실시하기 위한 전문가를 위한 정기적인 교육 세션을 제공합니다. 질병 부담이 증가함에 따라 진단율도 증가하고 있습니다. 진단의 발전으로 진단을 받는 사람들의 비율도 증가하고 있습니다.

  • 홈케어 테스트 선호도 상승

홈 헬스케어 선호도는 적절한 장소와 시간에 임상 정보를 제공합니다. 또한 오류를 줄이고 품질을 보장하여 안전을 높이는 데 도움이 됩니다. 또한 의료 응급 상황에서 노인을 돕습니다. 진료 시점 검사의 이점을 해결하기 위해 헬스케어에서 많은 전략적 변화가 이루어졌습니다. 세계보건기구(WHO)에 따르면 65세 이상 인구는 2010년의 약 5억 2,400만 명에서 2050년에는 약 15억 명으로 증가할 것으로 예상되며, 선진국이 증가의 대부분을 차지할 것입니다.

분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장

기회

  • 시장 참여자들이 취한 전략적 이니셔티브

전 세계적으로 만성 및 비만성 질환의 부담이 증가하고 아프리카와 아시아의 노인 인구가 증가함에 따라 더 나은 효능과 더 적은 시간 소모로 분자적 진료 시점 검사를 위한 새로운 키트와 솔루션 개발에 대한 수요가 증가했습니다. 이 지역에서 진단과 스크리닝을 제공하기 위해 시장의 주요 업체는 파트너십과 계약을 통해 키트와 기기를 통해 전 세계 인구에게 양질의 치료를 제공합니다.

  • 의료비 지출 증가

의료비 지출과 인프라를 늘리면 환자가 번거롭지 않은 고급 치료를 받아 더 나은 진단, 시술 및 빠른 회복을 위한 치료를 받을 수 있습니다. 진료 시점 검사 장치는 다양한 질병을 탐지하고 POC 소프트웨어와 솔루션을 사용하여 치료 계획을 지원하는 데 유용합니다. 의료비 지출은 개인 부담금(환자가 치료비를 지불하는 것), 정부 지출, 건강 보험 및 비정부 기구의 활동을 포함한 소스로 구성됩니다.

제약/도전

  • 높은 제품 비용

진료 시점 테스트 제품은 개발 프로세스에 상당한 비용이 필요합니다. 개념을 확정해야 하므로 재료를 조달해야 하며 리드 타임을 고려하는 것이 필수적입니다. 또한, 기기 설계가 시장에 출시되기 전에 완전히 성숙할 수 있는 충분한 시간이 필요하기 때문에 프로세스가 시간이 많이 걸립니다.

  • 실험실에서 얻은 테스트 결과와 일치하지 않음

실험실 테스트 표준의 결과와 비교했을 때, NAAT 테스트 결과는 다릅니다. 실험실 테스트는 더 발전되어 있으며, 실험실 테스트를 위한 프로세스, 프로토콜 및 과학을 따르며, 효과를 정확하게 분석, 검증 및 문서화하는 데 필요한 기술과 완전히 통합됩니다. 그러나 POCT/NAAT는 의심할 여지 없이 정확한 결과의 부족과 관련이 있습니다. 분자 POCT는 표준화를 완료할 수 없으며, 다른 중요한 기준은 표준화 및 다양한 필수 표준을 달성할 수 없습니다. 이는 글로벌 분자적 진료 시점 테스트 시장에 상당한 도전입니다. PoC 테스트는 때때로 잘못된 결과를 제공하고 테스트 결과 변동성을 겪을 수 있습니다.

COVID-19 이후 글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장에 미치는 영향

COVID-19는 분자적 진료 시점 검사(NAAT 사용) 시장에 큰 영향을 미쳤습니다. COVID-19는 점진적인 온라인 판매와 제품의 기술 발전으로 인해 분자적 진료 시점 검사(NAAT 사용) 제품의 가격과 수요에 더 높은 수준의 긍정적인 영향을 미쳤습니다. COVID-19 팬데믹 발발은 특히 다양한 병원에서 분자적 진료 시점 검사(NAAT 사용)에 대한 높은 수요로 인해 시장 성장에 긍정적인 영향을 미쳤습니다. 대부분 병원에서 현재 우선순위는 COVID-19 치료에 주어지고 있는데, COVID-19 사례의 급증이 여전히 지속되고 있기 때문에 분자적 진료 시점 검사(NAAT 사용)의 사용도 증가하고 있습니다. 게다가 많은 국제 정부와 의료 기관이 이러한 제품의 공급을 지원하여 중대한 경우에 대한 우선순위가 높기 때문입니다.

최근 개발 사항

  • 2021년 11월, F.Hoffmann-La Roche Ltd는 Roche가 13년째 Dow Jones Sustainability Indices에서 가장 지속 가능한 헬스케어 기업 3위 안에 들었다고 발표했습니다. 이를 통해 예측 기간 동안 사업 수행 용량과 사업 확장이 증가했습니다.
  • 2021년 10월 Thermo Fisher Scientific Corporation은 TaqMan COVId-19 검사 SARS-COV 분자 검사에 대한 FDA 승인을 받았습니다. 이를 통해 회사의 제품 포트폴리오가 증가하고 예측 기간 동안 회사 수익에 기여했습니다.

글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장 범위

글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장은 제품, 적응증, 최종 사용자, 테스팅 모드, 유통 채널을 기준으로 5개의 주요 세그먼트로 분류됩니다. 이러한 세그먼트의 성장은 산업의 시장 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내리는 데 도움이 되는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 될 것입니다.

제품

  • 악기
  • 소모품 및 시약

제품을 기준으로 볼 때, 글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 장비, 소모품, 시약으로 구분됩니다.

표시

  • 성병(STI) 검사
  • 호흡기 감염 검사
  • 위장관 감염 검사
  • 기타

글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 적응증을 기준으로 성병(STI) 검사, 호흡기 감염 검사, 위장관 감염 검사 및 기타 검사로 구분됩니다.

최종 사용자

  • 실험실
  • 병원
  • 클리닉
  • 외래 진료 센터
  • 홈 케어
  • 보조 생활 시설
  • 기타

최종 사용자를 기준으로, 글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 실험실, 병원, 진료소, 외래 진료소, 가정 간병 시설, 보호 시설 및 기타로 구분됩니다.

테스트 모드

  • 처방 기반 테스트
  • OTC 테스트

테스트 방식을 기준으로 볼 때, 글로벌 분자적 진료 시점 테스트(NAAT 사용) 시장은 처방 기반 테스트와 OTC 테스트로 구분됩니다 .

유통 채널

  • 병원 약국
  • 소매 약국
  • 온라인 약국

분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장

글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 유통 채널을 기준으로 병원 약국, 소매 약국, 온라인 약국으로 구분됩니다.

글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장 지역 분석/통찰력

글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 제품, 적응증, 최종 사용자, 검사 방식 및 유통 채널을 기준으로 5개의 주요 세그먼트로 분류됩니다.

글로벌 분자적 진료 시점 검사(NAAT 사용) 시장은 북미(미국, 캐나다), 유럽(영국, 독일, 프랑스, ​​스페인, 이탈리아, 유럽 기타 지역), 남아시아(파키스탄, 방글라데시, 인도, 남아시아 기타 지역), 동남아시아(싱가포르, 말레이시아, 베트남, 인도네시아, 태국, 필리핀, 동남아시아 기타 지역), 중동(사우디 아라비아, UAE, 이집트, 이스라엘, 중동 기타 지역), 아프리카(남아프리카, 케냐, 나이지리아, 아프리카 기타 지역)로 분류됩니다.

분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장

북미는 시장 점유율과 시장 수익 측면에서 약 12.1%의 CAGR로 글로벌 분자적 진료 시점 검사(NAAT 사용) 시장을 지배하고 있습니다. 예측 기간 동안에도 지배력이 계속될 것입니다. 이는 감염성 및 만성 질환의 유병률이 증가하고 병원에서 진료 시점 검사를 도입했기 때문입니다.

경쟁 환경 및 글로벌 분자적 포인트 오브 케어 테스트(NAAT 사용) 시장 점유율 분석

글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 구성 요소는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 규제 지침, 브랜드 분석, 제품 승인, 제품 탑재량, 애플리케이션 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 케어 테스팅(NAAT 사용) 시장의 글로벌 분자적 주제에 대한 회사의 초점과만 관련이 있습니다.

Danaher는 시장을 지배하는 플레이어입니다. 글로벌 분자적 포인트 오브 케어 테스팅(NAAT 사용) 시장에서 운영되는 다른 주요 플레이어로는 SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., binx Health, Inc., Lucira, Meridian Bioscience, Quantumdx Group Ltd., BD, Biomérieux Sa, Qiagen, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories, Inc., Sekisui Diagnostic, Randox Laboratories Ltd., GenMark Diagnostics, Seegene Inc. Grifols SA, Wondfo, Oxford Nanopore Diagnostic, PerkinElmer Inc., Co-Diagnostic 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DISTRIBUTION CHANNEL LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES

4.3.1 CEPHEID

4.3.2 THERMO FISHER SCIENTIFIC INC.

4.3.3 HOLOGIC, INC.

4.3.4 BD

4.3.5 F. HOFFMANN-LA ROCHE LTD

4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY

4.5 DISTRIBUTORS

4.5.1 NORTH AMERICA

4.5.2 EUROPE

4.5.3 SOUTH ASIA

4.5.4 SOUTH EAST ASIA

4.5.5 MIDDLE EAST

4.5.6 AFRICA

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

6.1.2 IMPROVING DIAGNOSIS SEEKING RATE

6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS

6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE

6.1.5 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 PRODUCT RECALLS

6.2.2 HIGH COSTS OF PRODUCTS

6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 PANDEMIC OUTBREAK OF COVID-19

6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 LACK OF ACCESSIBILITY

7 IMPACT OF COVID-19 ON THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19

7.5 CONCLUSION:

8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & REAGENTS

8.3 INSTRUMENTS

8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)

8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)

9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS TESTING

9.2.1 COVID-19

9.2.2 FLU B

9.2.3 FLU A

9.2.4 RSV

9.2.5 TUBERCULOSIS

9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)

9.2.7 OTHERS

9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING

9.3.1 TV

9.3.2 CT

9.3.3 NG

9.3.4 HPV

9.3.5 HSV

9.3.6 MG

9.3.7 UU

9.3.8 MH

9.3.9 OTHERS

9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING

9.4.1 GROUP B STREPTOCOCCUS

9.4.2 SHIGA TOXIN

9.4.3 H. PYLORI

9.5 OTHERS

10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER

10.1 OVERVIEW

10.2 LABORATORIES

10.2.1 POLYMERASE CHAIN REACTION

10.2.2 ISOTHERMAL AMPLIFICATION

10.3 HOSPITAL

10.3.1 POLYMERASE CHAIN REACTION

10.3.2 ISOTHERMAL AMPLIFICATION

10.4 CLINICS

10.4.1 POLYMERASE CHAIN REACTION

10.4.2 ISOTHERMAL AMPLIFICATION

10.5 AMBULATORY CENTER

10.5.1 POLYMERASE CHAIN REACTION

10.5.2 ISOTHERMAL AMPLIFICATION

10.6 HOMECARE

10.6.1 POLYMERASE CHAIN REACTION

10.6.2 ISOTHERMAL AMPLIFICATION

10.7 ASSISTED LIVING FACILITIES

10.7.1 POLYMERASE CHAIN REACTION

10.7.2 ISOTHERMAL AMPLIFICATION

10.8 OTHERS

11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING

11.1 OVERVIEW

11.2 PRESCRIPTION-BASED TESTING

11.3 OTC TESTING

12 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACY

12.3 RETAIL PHARMACY

12.4 ONLINE PHARMACY

13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION

13.1 OVERVIEW

13.2 NORTH AMERICA

13.2.1 U.S.

13.2.2 CANADA

13.3 EUROPE

13.3.1 U.K.

13.3.2 GERMANY

13.3.3 ITALY

13.3.4 FRANCE

13.3.5 SPAIN

13.3.6 REST OF EUROPE

13.4 SOUTH ASIA

13.4.1 INDIA

13.4.2 PAKISTAN

13.4.3 BANGLADESH

13.4.4 REST OF SOUTH ASIA

13.5 SOUTH EAST ASIA

13.5.1 SINGAPORE

13.5.2 VIETNAM

13.5.3 THAILAND

13.5.4 MALAYSIA

13.5.5 INDONESIA

13.5.6 PHILIPPINES

13.5.7 REST OF SOUTH EAST ASIA

13.6 MIDDLE EAST

13.6.1 SAUDI ARABIA

13.6.2 U.A.E

13.6.3 ISRAEL

13.6.4 EGYPT

13.6.5 REST OF MIDDLE EAST

13.7 AFRICA

13.7.1 SOUTH AFRICA

13.7.2 KENYA

13.7.3 NIGERIA

13.7.4 REST OF AFRICA

14 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

14.3 COMPANY SHARE ANALYSIS: EUROPE

14.4 COMPANY SHARE ANALYSIS: SOUTH ASIA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 DANAHER

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 THERMO FISHER SCIENTIFIC INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 BD

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 F.HOFFMANN-LA-ROCHE LTD.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 ABBOTT

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 BINX HEALTH, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 BIOMERIEUX SA

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 CO-DIAGNOSTICS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 GENMARK DIAGNOSTICS, INC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 GRIFOLS, S.A.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 LUCIRA HEALTH INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 MERIDIAN BIOSCIENCE

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 QUANTUMDX GROUP LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 QUIDEL CORPORATION

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 SD BIOSENSOR, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 WONDFO

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

표 목록

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 8 DISTRIBUTORS ACROSS EUROPE

TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 12 DISTRIBUTORS ACROSS AFRICA

TABLE 13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 14 GLOBAL CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 17 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 18 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 20 GLOBAL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 GLOBAL SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 22 GLOBAL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 24 GLOBAL OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 26 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 28 GLOBAL HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 GLOBAL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 30 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 32 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 34 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 36 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 38 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 40 GLOBAL PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 41 GLOBAL OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 GLOBAL HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 GLOBAL RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 GLOBAL ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 58 NORTH AMERICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 60 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 61 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 62 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 63 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 64 U.S. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 65 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 66 U.S. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 67 U.S. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 68 U.S. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 69 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 70 U.S. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 71 U.S. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 72 U.S. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 73 U.S. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 74 U.S. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 75 U.S. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 76 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 77 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 78 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 79 CANADA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 80 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 81 CANADA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 82 CANADA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 83 CANADA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 84 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 85 CANADA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 CANADA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 87 CANADA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 88 CANADA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 89 CANADA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 90 CANADA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 92 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 94 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 95 EUROPE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 96 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 97 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 98 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 99 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 100 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 101 EUROPE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 102 EUROPE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 103 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 104 EUROPE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 105 EUROPE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 106 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 107 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 108 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 109 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 110 U.K. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 111 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 112 U.K. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 113 U.K. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 114 U.K. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 115 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 116 U.K. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 117 U.K. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 118 U.K. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 119 U.K. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 120 U.K. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 121 U.K. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 122 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 123 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 124 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 125 GERMANY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 126 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 127 GERMANY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 GERMANY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 129 GERMANY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 130 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 131 GERMANY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 132 GERMANY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 133 GERMANY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 134 GERMANY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 135 GERMANY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 136 GERMANY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 137 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 138 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 139 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 140 ITALY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 141 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 142 ITALY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 143 ITALY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 144 ITALY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 145 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 ITALY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 147 ITALY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 148 ITALY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 149 ITALY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 150 ITALY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 151 ITALY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 152 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 153 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 154 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 155 FRANCE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 156 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 157 FRANCE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 158 FRANCE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 159 FRANCE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 160 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 161 FRANCE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 162 FRANCE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 163 FRANCE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 164 FRANCE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 165 FRANCE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 166 FRANCE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 167 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 168 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 169 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 170 SPAIN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 171 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 172 SPAIN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 173 SPAIN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 174 SPAIN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 175 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 176 SPAIN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 177 SPAIN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 178 SPAIN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 179 SPAIN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 180 SPAIN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 181 SPAIN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 182 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 183 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 184 REST OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 185 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 186 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 187 SOUTH ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 188 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 189 SOUTH ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 190 SOUTH ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 191 SOUTH ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 192 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 193 SOUTH ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 194 SOUTH ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 195 SOUTH ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 196 SOUTH ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 197 SOUTH ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 198 SOUTH ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 199 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 200 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 201 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 202 INDIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 203 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 204 INDIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 205 INDIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 206 INDIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 207 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 208 INDIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 209 INDIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 210 INDIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 211 INDIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 212 INDIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 213 INDIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 214 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 215 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 216 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 217 PAKISTAN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 218 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 219 PAKISTAN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 220 PAKISTAN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 221 PAKISTAN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 222 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 223 PAKISTAN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 224 PAKISTAN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 225 PAKISTAN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 226 PAKISTAN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 227 PAKISTAN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 228 PAKISTAN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 229 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 230 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 231 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 232 BANGLADESH INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 233 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 234 BANGLADESH RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 235 BANGLADESH SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 236 BANGLADESH GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 237 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 238 BANGLADESH LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 239 BANGLADESH HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 240 BANGLADESH CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 241 BANGLADESH AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 242 BANGLADESH HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 243 BANGLADESH ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 244 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 245 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 246 REST OF SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 247 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 248 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 249 SOUTH EAST ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 250 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 251 SOUTH EAST ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 252 SOUTH EAST ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 253 SOUTH EAST ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 254 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 255 SOUTH EAST ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 256 SOUTH EAST ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 257 SOUTH EAST ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 258 SOUTH EAST ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 259 SOUTH EAST ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 260 SOUTH EAST ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 261 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 262 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 263 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 264 SINGAPORE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 265 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 266 SINGAPORE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 267 SINGAPORE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 268 SINGAPORE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 269 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 270 SINGAPORE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 271 SINGAPORE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 272 SINGAPORE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 273 SINGAPORE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 274 SINGAPORE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 275 SINGAPORE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 276 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 277 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 278 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 279 VIETNAM INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 280 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 281 VIETNAM RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 282 VIETNAM SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 283 VIETNAM GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 284 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 VIETNAM LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 286 VIETNAM HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 287 VIETNAM CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 288 VIETNAM AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 289 VIETNAM HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 290 VIETNAM ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 291 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 292 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 293 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 294 THAILAND INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 295 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 296 THAILAND RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 297 THAILAND SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 298 THAILAND GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 299 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 300 THAILAND LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 301 THAILAND HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 302 THAILAND CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 303 THAILAND AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 304 THAILAND HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 305 THAILAND ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 306 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 307 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 308 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 309 MALAYSIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 310 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 311 MALAYSIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 312 MALAYSIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 313 MALAYSIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 314 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 315 MALAYSIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 316 MALAYSIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 317 MALAYSIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 318 MALAYSIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 319 MALAYSIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 320 MALAYSIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 321 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 322 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 323 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 324 INDONESIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 325 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 326 INDONESIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 327 INDONESIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 328 INDONESIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 329 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 330 INDONESIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 331 INDONESIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 332 INDONESIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 333 INDONESIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 334 INDONESIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 335 INDONESIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 336 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 337 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 338 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 339 PHILIPPINES INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 340 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 341 PHILIPPINES RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 342 PHILIPPINES SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 343 PHILIPPINES GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 344 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 345 PHILIPPINES LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 346 PHILIPPINES HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 347 PHILIPPINES CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 348 PHILIPPINES AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 349 PHILIPPINES HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 350 PHILIPPINES ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 351 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 352 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 353 REST OF SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 354 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 355 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 356 MIDDLE EAST INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 357 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 358 MIDDLE EAST RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 359 MIDDLE EAST SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 360 MIDDLE EAST GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 361 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 362 MIDDLE EAST LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 363 MIDDLE EAST HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 364 MIDDLE EAST CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 365 MIDDLE EAST AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 366 MIDDLE EAST HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 367 MIDDLE EAST ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 368 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 369 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 370 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 371 SAUDI ARABIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 372 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 373 SAUDI ARABIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 374 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 375 SAUDI ARABIAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 376 SAUDI ARABIAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 377 SAUDI ARABIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 378 SAUDI ARABIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 379 SAUDI ARABIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 380 SAUDI ARABIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 381 SAUDI ARABIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 382 SAUDI ARABIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 383 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 384 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 385 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 386 U.A.E INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 387 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 388 U.A.E RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 389 U.A.E SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 390 U.A.E GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 391 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 392 U.A.E LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 393 U.A.E HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 394 U.A.E CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 395 U.A.E AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 396 U.A.E HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 397 U.A.E ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 398 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 399 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 400 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 401 ISRAEL INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 402 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 403 ISRAEL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 404 ISRAEL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 405 ISRAEL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 406 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 407 ISRAEL LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 408 ISRAEL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 409 ISRAEL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 410 ISRAEL AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 411 ISRAEL HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 412 ISRAEL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 413 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 414 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 415 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 416 EGYPT INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 417 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 418 EGYPT RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 419 EGYPT SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 420 EGYPT GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 421 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 422 EGYPT LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 423 EGYPT HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 424 EGYPT CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 425 EGYPT AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 426 EGYPT HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 427 EGYPT ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 428 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 429 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 430 REST OF MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 431 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 432 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 433 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 434 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 435 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 436 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 437 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 438 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 439 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 440 AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 441 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 442 AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 443 AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 444 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 445 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 446 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 447 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 448 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 449 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 450 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 451 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 452 SOUTH AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 453 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 454 SOUTH AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 455 SOUTH AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 456 SOUTH AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 457 SOUTH AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 458 SOUTH AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 459 SOUTH AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 460 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 461 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 462 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 463 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 464 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 465 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 466 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 467 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 468 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 469 KENYA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 470 KENYA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 471 KENYA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 472 KENYA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 473 KENYA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 474 KENYA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 475 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 476 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 477 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 478 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 479 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 480 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 481 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 482 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 483 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 484 NIGERIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 485 NIGERIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 486 NIGERIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 487 NIGERIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 488 NIGERIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 489 NIGERIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 490 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 491 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 492 REST OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

그림 목록

FIGURE 1 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 2 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING

FIGURE 8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID

FIGURE 11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD

FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028

FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE MOLECULAR POINT OF CARE TESTING (USING NAAT) MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

FIGURE 17 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 18 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020

FIGURE 19 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 20 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 21 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 22 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020

FIGURE 23 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 24 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 26 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020

FIGURE 27 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 28 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)

FIGURE 29 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020

FIGURE 31 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)

FIGURE 32 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)

FIGURE 33 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE

FIGURE 34 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 36 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020)

FIGURE 40 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2021 & 2028)

FIGURE 41 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020 & 2028)

FIGURE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 43 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 44 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 45 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 48 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 49 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 50 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 51 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 52 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 53 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 54 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 55 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 56 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 57 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 58 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 59 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 60 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 61 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 62 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 63 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 64 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 65 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 66 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 67 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 68 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 69 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 70 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 71 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 72 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 73 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

FIGURE 74 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

FIGURE 75 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

FIGURE 76 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

Testimonial